8-K filing — Upstream Bio, Inc. (UPB)

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, a TSLP receptor antagonist, showing a 56% reduction in annualized asthma exacerbation rate at 100 mg every 12 weeks versus placebo. The company plans to initiate Phase 3 trials in Q1 2027 evaluating a 400 mg quarterly dosing regimen in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

Upstream Bio Presented Results From The Phase 2 VALIANT Clinical Trial Evaluating The Safety And Efficacy Of Verekitug In Adults With Severe Asthma In A Late-breaking Oral Presentation At The European Respiratory Society Congress 2026 In Barcelona

HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.

Upstream Bio Announces Phase 3 Plans For Verekitug At 400 mg Every 12 Weeks In Severe Asthma And CRSwNP, With About 1,500 Patients Across Two Placebo-Controlled Trials; On Track To Initiate Q1 2027